Swim through the sea of acronyms as Dr Scott Matherly (@liverprof) helps us become a little less baffled by the thought of NAFLD. We discuss the initial diagnosis of fatty liver disease, indications for additional evaluation with imaging and/or biopsy, and potential treatment options. With a quarter of the world affected, it’s crucial to understand the various forms of disease and how to counsel patients about this all-too-common condition!
Show Notes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com | Free CME!
Credits
- Written and Produced by: Elena Gibson MD
- Infographic and Cover Art: Elena Gibson MD
- Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP
- Editor: Emi Okamoto MD (written materials); Clair Morgan of nodderly.com
- Guest: Scott Matherly MD
Sponsor: Pediatrics On Call
Sponsor: VCU Health Continuing Education to offer continuing education credits for physicians and other healthcare professionals. Check out curbsiders.vcuhealth.org and create your FREE account!
Time Stamps
00:00 Intro
03:15 Guest one-liner; Picks of the Week*
:
08:15 Sponsor
08:50 Case from Kashlak part 1; What is hepatic steatosis?
11:43 NAFLD acronyms and definitions
18:20 Alcohol and Fatty Liver
23:15 Initial Evaluation of NAFLD
35:12 Dr Matherly’s piel to patients with fatty
41:11 NASH/Fibrosis Risk Assessment
48:54 Outcomes in NASH with Fibrosis
51:20 Statins are safe in liver disease
56:15 Treatment Options (surgery, Vitamin E, Pioglitazone, SLGT2 inhibitors and GLP1 agonists; Coffee?!)
71:42 Take home points and Outro
